OncoMatch/Clinical Trials/NCT07218146
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Is NCT07218146 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including ZL-1310 and Investigator's Choice of Therapy for small-cell lung cancer.
Treatment: ZL-1310 · Investigator's Choice of Therapy — The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — first-line
Received 1L platinum-based systemic therapy and had documented disease progression during or after the most recent systemic therapy
Cannot have received: antibody-drug conjugate
Exception: ADC with topoisomerase 1 inhibitor payload
Received any prior ADC with topoisomerase 1 inhibitor payload
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Zai Lab Site 02045 · Clermont, Florida
- Zai Lab Site 02031 · Orange City, Florida
- Zai Lab Site 02020 · Rockledge, Florida
- Zai Lab Site 02026 · Sarasota, Florida
- Zai Lab Site 02021 · Peoria, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify